The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure

Journal of Cardiac Failure

Volumn 21, Issue 1, 2015, Pages 51-59

  Zhang, Yuhui ^a   Zhang, Rongcheng ^a   An, Tao ^a   Huang, Yan ^a   Guo, Xiao ^a   Yin, Shijie ^a   Wang, Yunhong ^a   Ji, Shiming ^a   Lv, Rong ^a   Zhang, Jian ^a   Maisel, Alan ^b  

^a FUWAI HOSPITAL   (China)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

death; Galectin 3; heart failure; prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; GALECTIN-3, HUMAN;

ADULT; ARTICLE; CAUSE OF DEATH; CLASSIFICATION; DEATH; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK FACTOR; AGED; BLOOD; COHORT ANALYSIS; HOSPITALIZATION; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; TRENDS;

ADULT; AGED; BIOLOGICAL MARKERS; CAUSE OF DEATH; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 84919599204     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2014.10.006     Document Type: Article

References (28)

1. L.R. Loehr, W.D. Rosamond, P.P. Chang, A.R. Folsom, and L.E. Chambless Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study) Am J Cardiol 101 2008 1016 1022
2. S. Sanada, D. Hakuno, L.J. Higgins, E.R. Schreiter, A.N. McKenzie, and R.T. Lee IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system J Clin Invest 117 2007 1538 1549
3. U.C. Sharma, S. Pokharel, T.J. van Brakel, J.H. van Berlo, J.P. Cleutjens, and B. Schroen Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 110 2004 3121 3128
4. R.A. de Boer, L. Yu, and D.J. van Veldhuisen Galectin-3 in cardiac remodeling and heart failure Curr Heart Fail Rep 7 2010 1 8
5. T. Socrates, C. deFilippi, T. Reichlin, R. Twerenbold, T. Breidhardt, and M. Noveanu Interleukin family member ST2 and mortality in acute dyspnoea J Intern Med 268 2010 493 500
6. E.W. Grandin, P. Jarolim, S.A. Murphy, L. Ritterova, C.P. Cannon, and E. Braunwald Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22 Clin Chem 58 2012 267 273
7. R.R. van Kimmenade, J.L. Januzzi Jr., P.T. Ellinor, U.C. Sharma, J.A. Bakker, and A.F. Low Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure J Am Coll Cardiol 48 2006 1217 1224
8. D.J. Lok, P. van der Meer, P.W. de la Porte, E. Lipsic, J. Van Wijngaarden, and H.L. Hillege Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study Clin Res Cardiol 99 2010 323 328
9. R.V. Shah, A.A. Chen-Tournoux, M.H. Picard, R.R. van Kimmenade, and J.L. Januzzi Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure Eur J Heart Fail 12 2010 826 832
10. R.A. de Boer, D.J. Lok, T. Jaarsma, P. van der Meer, A.A. Voors, and H.L. Hillege Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann Med 43 2011 60 68
11. G.M. Felker, M. Fiuzat, L.K. Shaw, R. Clare, D.J. Whellan, and L. Bettari Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study Circ Heart Fail 5 2012 72 78
12. T. Ahmad, M. Fiuzat, B. Neely, M.L. Neely, M.J. Pencina, and W.E. Kraus Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure JACC Heart Fail 2 2014 260 268
13. Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology Guidelines for the diagnosis and management of chronic heart failure Zhonghua Xin Xue Guan Bing Za Zhi 35 2007 1076 1095
14. Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology Practice Guideline Guideline for diagnosis and treatment of acute heart failure Zhonghua Xin Xue Guan Bing Za Zhi 38 2010 195 208
15. R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, and P.A. Pellikka Recommendations for chamber quantification Eur J Echocardiogr 7 2006 79 108
16. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
17. R.N. Pugh, I.M. Murray-Lyon, J.L. Dawson, M.C. Pietroni, and R. Williams Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 1973 646 649
18. M.J. Pencina, R.B. d'Agostino Sr., and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 2011 11 21
19. S.H. Barondes, D.N. Cooper, M.A. Gitt, and Leffler H. Galectins Structure and function of a large family of animal lectins J Biol Chem 269 1994 20807 20810
20. D.N. Cooper Galectinomics: finding themes in complexity Biochim Biophys Acta 1572 2002 209 231
21. Y.H. Liu, M. d'Ambrosio, T.D. Liao, H. Peng, N.E. Rhaleb, and U. Sharma N-Acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin Am J Physiol Heart Circ Physiol 296 2009 H404 H412
22. R.A. Thandavarayan, K. Watanabe, M. Ma, P.T. Veeraveedu, N. Gurusamy, and S.S. Palaniyandi 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy Biochem Pharmacol 75 2008 1797 1806
23. N.C. Henderson, A.C. Mackinnon, S.L. Farnworth, F. Poirier, F.P. Russo, and J.P. Iredale Galectin-3 regulates myofibroblast activation and hepatic fibrosis Proc Natl Acad Sci U S A 103 2006 5060 5065
24. N.C. Henderson, A.C. Mackinnon, S.L. Farnworth, T. Kipari, C. Haslett, and J.P. Iredale Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis Am J Pathol 172 2008 288 298
25. D.M. Gopal, M. Kommineni, N. Ayalon, C. Koelbl, R. Ayalon, and A. Biolo Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure J Am Heart Assoc 1 2012 e000760
26. J.E. Ho, C. Liu, A. Lyass, P. Courchesne, M.J. Pencina, and R.S. Vasan Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community J Am Coll Cardiol 60 2012 1249 1256
27. A. Bayes-Genis, M. de Antonio, J. Vila, J. Penafiel, A. Galan, and J. Barallat Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3 J Am Coll Cardiol 63 2014 158 166
28. W.C. Meijers, J.L. Januzzi, C. deFilippi, A.S. Adourian, S.J. Shah, and D.J. van Veldhuisen Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials Am Heart J 167 2014 853 860.e4